Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Poly(ADP-Ribose) Polymerase Inhibitors [MoA]

Known as: Poly ADP Ribose Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase Inhibitors, Poly ADP-Ribose Polymerase Inhibitors 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Purpose: To define the prevalence of HER2 positive breast cancer (HER2+ BC) in women with gBRCA1/2-BC and to determine whether… Expand
Is this relevant?
2019
2019
Introduction: Ovarian cancer is a rare but often fatal disease and a leading cause of gynecologic cancer death, in the United… Expand
Is this relevant?
2018
2018
OBJECTIVE Homologous recombination (HR)-proficient ovarian tumors have poorer clinical outcomes and show resistance to poly ADP… Expand
Is this relevant?
Review
2018
Review
2018
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is… Expand
Is this relevant?
2018
2018
Poly(ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics with enhanced selectivity and cytotoxicity in BRCA1/2… Expand
  • figure 1
  • table 1
  • table 3
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARPI… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
1996
1996
Injury and inflammation lead to hypoxia and elevated lactate in wounds. This redox environment establishes cells in a reparative… Expand
Is this relevant?